Late-Preterm Betamethasone: Is This Common Pregnancy Practice Really Worth It?
"A closer look at the cost-effectiveness of antenatal corticosteroids in late-preterm pregnancies reveals surprising insights for expectant mothers."
For expectant parents navigating the complexities of pregnancy, especially when facing a late-preterm delivery (between 34 and 36 weeks gestation), decisions about medical interventions can feel overwhelming. One such intervention is the administration of antenatal corticosteroids, like betamethasone, aimed at improving neonatal respiratory outcomes. While this practice has become increasingly common, a critical question remains: Is it truly cost-effective?
A recent study published in The Journal of Maternal-Fetal & Neonatal Medicine sheds light on this very question, offering a detailed cost-effectiveness analysis of betamethasone administration in late-preterm gestations. The findings might surprise you, challenging the assumption that this standard of care always provides the best value.
This article breaks down the study's methodology, results, and implications, empowering you with the knowledge to have informed conversations with your healthcare providers and make the best decisions for your unique situation. We'll explore the potential benefits and risks, offering a balanced perspective grounded in evidence-based research.
Current Evidence and Impact
The 2016 ALPS trial found that administering betamethasone to women at risk for late-preterm delivery significantly reduced neonatal respiratory complications. A 2024 study, however, reported that additional betamethasone courses could not be supported in an unselected population, while suggesting possible benefit in a high-risk population that has not yet been defined. A 2025 systematic review evaluates antenatal corticosteroids at 34 0/7 to 36 6/7 weeks but notes limitations, including insufficient information about gestational age at administration and pregnancy-related factors that could affect neurologic outcomes.
A Careful, Individualized Approach
Late-preterm betamethasone decisions generally require balancing the possibility of respiratory benefit against uncertainty about whether delivery will occur soon enough for treatment to help. The evidence does not establish that every patient benefits equally, so clinicians may need to consider the likelihood and timing of delivery alongside individual pregnancy circumstances. Because the supporting evidence has important limitations, treatment decisions should remain individualized rather than automatic.
From Early Lung Maturation Therapy to ALPS
Antenatal corticosteroids became a well-established treatment for fetal lung maturation before 34 + 0 weeks of gestation. Their use in the late-preterm period, defined in the cited commentary as 34 + 0 to 36 + 6 weeks, remained an area of ongoing debate. The NICHD/MFMU ALPS Trial was a randomized controlled trial conducted at 17 university-based medical centers from 2010 to 2015, enrolling 2,831 women with singleton pregnancies at 34 + 0 to 36 + 5 weeks who had a high probability of late-preterm delivery. Subsequent research has also examined long-term neurodevelopmental outcomes after late-preterm betamethasone exposure.
The Core Question: Does Betamethasone Really Save Money and Improve Outcomes?
The study employed a cost-effectiveness analysis, a method used to compare the costs of a medical intervention with its benefits. Researchers built a model using data from the 'Antenatal Betamethasone for Women at Risk for Late Preterm Delivery' (ALPS) trial and other sources to simulate the outcomes and costs associated with betamethasone administration versus no administration in late-preterm pregnancies.
- Neonatal outcomes: Respiratory distress syndrome (RDS), transient tachypnea of the newborn (TTN), and hypoglycemia (low blood sugar)
- Healthcare costs: Hospital costs associated with these outcomes, as well as the cost of betamethasone itself.
- Quality-adjusted life years (QALYs): A measure that combines both the length and quality of life, allowing researchers to assess the overall health benefit of each intervention.
An Evidence Base Still Evolving
Recent reviews and studies continue to assess whether late-preterm antenatal corticosteroids improve outcomes across different patient groups. Current uncertainty reflects differences in gestational age, reasons for treatment, pregnancy complications, and the likelihood that delivery will occur soon. The most useful future evidence will likely come from research that more clearly identifies which patients are at sufficiently high risk to benefit.
The Risk of Treating the Wrong Pregnancy
After the ALPS Trial, antenatal corticosteroids became standard care for patients at risk of late-preterm delivery. The cited study raises concern that term newborns exposed to preterm antenatal corticosteroids may face increased risks of adverse outcomes. This highlights a central limitation of treatment based on uncertain delivery timing: exposure intended for a preterm birth may occur even when the newborn ultimately reaches term.
Who Meets Current Eligibility Criteria?
The 2025 SMFM guidance reaffirmed Consult Series #58, which remains endorsed by ACOG according to the cited guidance summary. Eligibility is described as a singleton pregnancy at 34 0/7 to 36 6/7 weeks with a high probability of delivery within 7 days. The recommended regimen is two 12 mg intramuscular betamethasone doses administered 24 hours apart, rather than routine treatment for all late-preterm pregnancies.
Empowering Informed Decisions for Expectant Parents
Ultimately, the decision of whether or not to administer betamethasone in a late-preterm pregnancy is a complex one that should be made in consultation with your healthcare provider. This study provides valuable information to inform that conversation, highlighting the potential trade-offs between costs and benefits. By understanding the nuances of this intervention, you can advocate for the best possible care and ensure a healthy start for your little one.
Benefit Depends on Context
Late-preterm betamethasone may offer meaningful respiratory benefit when delivery is highly likely and occurs within the relevant treatment window. The same intervention is less straightforward when delivery timing is uncertain or when the patient does not match the population studied in major trials. A balanced interpretation therefore supports selective use, careful counseling, and continued attention to both short- and longer-term outcomes.
Refining Safety and Selection
In late-preterm premature rupture of membranes, betamethasone given with immediate delivery management was associated with fewer neonatal respiratory complications, although the reduction was not statistically significant. Maternal infectious morbidity was not increased in the cited study, while higher rates of neonatal sepsis and hypoglycemia were observed after betamethasone exposure. Future research will need to clarify which late-preterm PROM patients are most likely to benefit while minimizing these potential harms.
The Challenge of Clinical Uncertainty
The central systemic challenge is making a time-sensitive treatment decision when the exact timing of delivery may remain uncertain. Broad protocols can simplify care, but they may not capture differences in pregnancy complications, delivery probability, or newborn risk. More precise evidence could help clinicians apply treatment consistently without turning a selective intervention into a routine one.
Shared Decisions in a Narrow Window
For patients and clinicians, the decision often involves weighing a possible reduction in breathing problems against uncertainty about whether treatment is necessary. The discussion must account for the possibility that delivery will occur later than expected, as well as the potential for neonatal complications. Clear communication about what is known, what remains uncertain, and why treatment is being considered is therefore essential.